---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-219180"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:39:45.710217+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ACR-368 endometrial cancer Phase 2: 62.5% ORR in OncoSignature+ patients; ACR-2316 IND cleared

## Summary
- Confirmed ORR of 62.5% (95% CI 30.4-86.5) in prospectively-selected OncoSignature+ endometrial cancer patients who progressed on anti-PD-1.
- Statistically significant segregation of responders vs OncoSignature- arm (p=0.009); all responding patients still on therapy; mDoR not yet reached (~6 months).
- Endometrial cancer anticipated as first potential accelerated approval opportunity for ACR-368.
- FDA cleared IND for ACR-2316 (dual WEE1/PKMYT1 inhibitor); clinical sites activated; first-in-human dosing expected Q4 2024.
- Cash of $220.4M (June 30, 2024) expected to fund operations into H2 2026; guidance reiterated.

## SEC filing metadata
- accession: 0001193125-24-219180
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312524219180/0001193125-24-219180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312524219180/d355136d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-219180
- JSON: https://secwatch.observer/filing/0001193125-24-219180.json
- Plain text: https://secwatch.observer/filing/0001193125-24-219180.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.